Epizyme, Inc.

This early-stage trial tested whether adding a new drug, tazemetostat, to a standard chemotherapy (doxorubicin) was safe and could help control an ultra-rare and aggressive cancer called epithelioid sarcoma. The study was small and ended early, so it only gathered initial safety …